Indivior Pharmaceuticals (FRA:E7P) General and Admin. Expense: €0 Mil (TTM As of Mar. 2026)


FRA:E7P Indivior Pharmaceuticals Inc FRA:E7P
56 GF Score
Price €34.60
GF Value €19.18
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Indivior Pharmaceuticals General and Admin. Expense?

Indivior Pharmaceuticals FRA:E7P +4.85% 56 General and Admin. Expense is €0 Mil as of Mar. 2026. GuruFocus rates FRA:E7P with a GF Score™ of 56/100 and a GF Value™ of €19.18 (Significantly Overvalued). The stock has 6 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Indivior Pharmaceuticals's General and Admin. Expense for the three months ended in Mar. 2026 was €0 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €0 Mil.

Indivior Pharmaceuticals General and Admin. Expense Related Terms

Indivior Pharmaceuticals General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Indivior Pharmaceuticals's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indivior Pharmaceuticals General and Admin. Expense Chart

Indivior Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 211.52 236.94 301.69 340.94 272.43

Indivior Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:E7P
56GF Score
Indivior Pharmaceuticals Inc FRA:E7P
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indivior Pharmaceuticals General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of €0 Mil mean?
Indivior Pharmaceuticals (FRA:E7P) has a General and Admin. Expense of €0 Mil as of Mar. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Indivior Pharmaceuticals and its competitors.
Is Indivior Pharmaceuticals' General and Admin. Expense too high?
Indivior Pharmaceuticals' current General and Admin. Expense is €0 Mil. Overall, Indivior Pharmaceuticals has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Indivior Pharmaceuticals' General and Admin. Expense compare to AMRX and KNSA?
Indivior Pharmaceuticals' General and Admin. Expense of €0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Drug Manufacturers company?
A good General and Admin. Expense depends on the Drug Manufacturers industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Indivior Pharmaceuticals and its competitors. Indivior Pharmaceuticals's current General and Admin. Expense is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indivior Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Indivior Pharmaceuticals (FRA:E7P) is currently considered Significantly Overvalued. The stock's GF Value™ is €19.18, compared to a current price of €34.60 — trading 80.4% above its estimated fair value. The current General and Admin. Expense is €0 Mil. Indivior Pharmaceuticals' overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Indivior Pharmaceuticals (FRA:E7P), the current General and Admin. Expense is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Indivior Pharmaceuticals (FRA:E7P) Overvalued in 2026?

Based on GuruFocus' analysis, Indivior Pharmaceuticals stock appears to be overvalued. The current stock price of €34.60 is trading 80.4% above its estimated GF Value™ of €19.18. GuruFocus considers Indivior Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:E7P:

  • General and Admin. Expense: €0 Mil
  • GF Value™: €19.18 vs. price of €34.60 (80.4% above fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the FRA:E7P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Indivior Pharmaceuticals Business Description

Other Exchanges INDV:USA
Address 10710 Midlothian Turnpike, Suite 125, North Chesterfield, Richmond, VA, USA, 23235
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
56GF Score

Get the complete analysis for FRA:E7P

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€34.60
Price
€19.18
GF Value